降糖治疗对新诊断2型糖尿病血清色素上皮衍生因子的影响

Effect of Hypoglycemic Therapy on Serum Pigment Epithelium Derived Factor in Newly Diagnosed Type 2 Diabetes Mellitus

目的观察降糖治疗对新诊断的2型糖尿病患者血清色素上皮衍生因子水平的影响。方法选取2009年2月～2011年6月新诊断且在重庆医科大学附属第一医院住院治疗的2型糖尿病患者47例,经过短期胰岛素强化治疗后,将患者随机分为以二甲双胍为基础的口服药物组(OAD组)26例和甘精胰岛素组(GLA组)21例,以空腹血糖<7.2 mmol/L为治疗目标,降糖治疗6个月后,观察两组患者治疗前后血清PEDF浓度、空腹血糖、HbA1c、HOMA-β、HOMA-IR水平。结果经过6个月的降糖治疗,与基线比较,两组患者空腹血糖、HbA1C均降低,HOMA-β、PEDF均升高,差异有统计学意义(P<0.05);两组间空腹血糖、HbA1c、HOMA-β、PEDF比较,差异无统计学意义(P>0.05);HOMA-IR与基线比较,差异无统计学意义(P>0.05),两组间HOMA-IR比较,差异有统计学意义(P<0.05)。结论以二甲双胍为基础的口服药物降糖治疗和甘精胰岛素降糖治疗均可显著升高2型糖尿病患者的血清PEDF水平。

Objective To observe the effect of hypoglycemic therapy on serum pigment epithelial-derived factor levels in newly diagnosed type 2 diabetic patients.Methods A total of 47 patients with type 2 diabetes who were newly diagnosed and hospitalized in the First Affiliated Hospital of Chongqing Medical University from February 2009 to June 2011 were enrolled.After short-term intensive insulin therapy, the patients were randomly divided into the metformin-based oral drug group （OAD group） in 26 cases and the insulin glargine group （GLA group） in 21 cases, with fasting blood glucose 〈7.2 mmol/L as the treatment target. 6 months after the hypoglycemic treatment, serum PEDF concentration, fasting blood glucose, HbAlc, HOMA-β, and HOMA-IR levels were observed before and after treatment.Results After 6 months of hypoglycemic treatment, fasting blood glucose and HbAIC were decreased in both groups, and HOMA-β and PEDF were increased,the difference was statistically significant （P〈0.05）. Fasting blood glucose between the two groups, there was no significant difference in HbAlc, HOMA-[3 and PEDF （P〉0.05）. There was no significant difference between HOMA-IR and baseline （P〉0.05）. There was a statistically significant difference in HOMA-IR between the two groups （P〈0.05）. Conclusion Metformin-based oral drug hypoglycemic therapy and insulin glargine treatment can significantly increase serum PEDF levels in patients with type 2 diabetes.